Literature DB >> 25531824

Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants.

Herschel Mukherjee1, Kok-Ping Chan1, Vibeke Andresen2, Mariah L Hanley1, Bjørn Tore Gjertsen2,3, Andrew G Myers1.   

Abstract

Nucleophosmin (NPM1) is a multifunctional phosphoprotein localized predominantly within the nucleoli of eukaryotic cells. Mutations within its C-terminal domain are frequently observed in patients with acute myeloid leukemia (AML), are thought to play a key role in the initiation of the disease, and result in aberrant, cytoplasmic localization of the mutant protein. We have previously shown that the electrophilic antiproliferative natural product (+)-avrainvillamide (1) binds to proteins, including nucleophosmin, by S-alkylation of cysteine residues. Here, we report that avrainvillamide restores nucleolar localization of certain AML-associated mutant forms of NPM1 and provide evidence that this relocalization is mediated by interactions of avrainvillamide with mutant NPM1 and exportin-1 (Crm1). Immunofluorescence and mass spectrometric experiments employing a series of different NPM1 constructs suggest that a specific interaction between avrainvillamide and Cys275 of certain NPM1 mutants mediates the relocalization of these proteins to the nucleolus. Avrainvillamide treatment is also shown to inhibit nuclear export of Crm1 cargo proteins, including AML-associated NPM1 mutants. We also observe that avrainvillamide treatment displaces Thr199-phosphorylated NPM1 from duplicated centrosomes, leads to an accumulation of supernumerary centrosomes, and inhibits dephosphorylation of Thr199-phosphorylated NPM1 by protein phosphatase 1. Avrainvillamide is the first small molecule reported to relocalize specific cytoplasmic AML-associated NPM1 mutants to the nucleolus, providing an important demonstration of principle that small molecule induction of a wild-type NPM1 localization phenotype is feasible in certain human cancer cells.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25531824      PMCID: PMC4652655          DOI: 10.1021/cb500872g

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  47 in total

1.  Nucleophosmin suppresses oncogene-induced apoptosis and senescence and enhances oncogenic cooperation in cells with genomic instability.

Authors:  June Li; Daniel P Sejas; Sandeep Burma; David J Chen; Qishen Pang
Journal:  Carcinogenesis       Date:  2007-02-02       Impact factor: 4.944

Review 2.  Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features.

Authors:  Brunangelo Falini; Ildo Nicoletti; Massimo F Martelli; Cristina Mecucci
Journal:  Blood       Date:  2006-09-28       Impact factor: 22.113

3.  The natural product avrainvillamide binds to the oncoprotein nucleophosmin.

Authors:  Jeremy E Wulff; Romain Siegrist; Andrew G Myers
Journal:  J Am Chem Soc       Date:  2007-10-25       Impact factor: 15.419

4.  NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells.

Authors:  W Qi; K Shakalya; A Stejskal; A Goldman; S Beeck; L Cooke; D Mahadevan
Journal:  Oncogene       Date:  2008-03-17       Impact factor: 9.867

5.  Improved titanium dioxide enrichment of phosphopeptides from HeLa cells and high confident phosphopeptide identification by cross-validation of MS/MS and MS/MS/MS spectra.

Authors:  Li-Rong Yu; Zhongyu Zhu; King C Chan; Haleem J Issaq; Dimiter S Dimitrov; Timothy D Veenstra
Journal:  J Proteome Res       Date:  2007-10-09       Impact factor: 4.466

6.  The leukemia-associated cytoplasmic nucleophosmin mutant is an oncogene with paradoxical functions: Arf inactivation and induction of cellular senescence.

Authors:  K Cheng; S Grisendi; J G Clohessy; S Majid; R Bernardi; P Sportoletti; P P Pandolfi
Journal:  Oncogene       Date:  2007-06-04       Impact factor: 9.867

7.  Structural consequences of nucleophosmin mutations in acute myeloid leukemia.

Authors:  Charles G Grummitt; Fiona M Townsley; Christopher M Johnson; Alan J Warren; Mark Bycroft
Journal:  J Biol Chem       Date:  2008-05-29       Impact factor: 5.157

8.  Depletion of nucleophosmin leads to distortion of nucleolar and nuclear structures in HeLa cells.

Authors:  Mohammed Abdullahel Amin; Sachihiro Matsunaga; Susumu Uchiyama; Kiichi Fukui
Journal:  Biochem J       Date:  2008-11-01       Impact factor: 3.857

9.  Playing both sides: nucleophosmin between tumor suppression and oncogenesis.

Authors:  Pier Paolo Di Fiore
Journal:  J Cell Biol       Date:  2008-07-14       Impact factor: 10.539

10.  Nucleophosmin and its AML-associated mutant regulate c-Myc turnover through Fbw7 gamma.

Authors:  Paola Bonetti; Teresa Davoli; Cristina Sironi; Bruno Amati; Pier Giuseppe Pelicci; Emanuela Colombo
Journal:  J Cell Biol       Date:  2008-07-14       Impact factor: 10.539

View more
  13 in total

Review 1.  Heteroatom-Heteroatom Bond Formation in Natural Product Biosynthesis.

Authors:  Abraham J Waldman; Tai L Ng; Peng Wang; Emily P Balskus
Journal:  Chem Rev       Date:  2017-04-04       Impact factor: 60.622

2.  Inhibition of Mcl-1 through covalent modification of a noncatalytic lysine side chain.

Authors:  Gizem Akçay; Matthew A Belmonte; Brian Aquila; Claudio Chuaqui; Alexander W Hird; Michelle L Lamb; Philip B Rawlins; Nancy Su; Sharon Tentarelli; Neil P Grimster; Qibin Su
Journal:  Nat Chem Biol       Date:  2016-09-05       Impact factor: 15.040

3.  Cytoplasmic nucleophosmin has elevated T199 phosphorylation upon which G2/M phase progression is dependent.

Authors:  Narisa Chan; Tit Meng Lim
Journal:  Sci Rep       Date:  2015-06-30       Impact factor: 4.379

4.  A redox mechanism underlying nucleolar stress sensing by nucleophosmin.

Authors:  Kai Yang; Ming Wang; Yuzheng Zhao; Xuxu Sun; Yi Yang; Xie Li; Aiwu Zhou; Huilin Chu; Hu Zhou; Jianrong Xu; Mian Wu; Jie Yang; Jing Yi
Journal:  Nat Commun       Date:  2016-11-25       Impact factor: 14.919

Review 5.  Molecules that target nucleophosmin for cancer treatment: an update.

Authors:  Adele Di Matteo; Mimma Franceschini; Sara Chiarella; Serena Rocchio; Carlo Travaglini-Allocatelli; Luca Federici
Journal:  Oncotarget       Date:  2016-07-12

6.  Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.

Authors:  Vibeke Andresen; Bjarte S Erikstein; Herschel Mukherjee; André Sulen; Mihaela Popa; Steinar Sørnes; Håkon Reikvam; Kok-Ping Chan; Randi Hovland; Emmet McCormack; Øystein Bruserud; Andrew G Myers; Bjørn T Gjertsen
Journal:  Cell Death Dis       Date:  2016-12-01       Impact factor: 8.469

Review 7.  Drug Repurposing for the Treatment of Acute Myeloid Leukemia.

Authors:  Vibeke Andresen; Bjørn T Gjertsen
Journal:  Front Med (Lausanne)       Date:  2017-11-29

8.  Chromosomal passenger complex hydrodynamics suggests chaperoning of the inactive state by nucleoplasmin/nucleophosmin.

Authors:  Mariah L Hanley; Tae Yeon Yoo; Matthew Sonnett; Daniel J Needleman; Timothy J Mitchison
Journal:  Mol Biol Cell       Date:  2017-04-12       Impact factor: 4.138

Review 9.  Nucleophosmin in Its Interaction with Ligands.

Authors:  Ilaria Cela; Adele Di Matteo; Luca Federici
Journal:  Int J Mol Sci       Date:  2020-07-10       Impact factor: 5.923

10.  Conformational stabilization as a strategy to prevent nucleophosmin mislocalization in leukemia.

Authors:  María A Urbaneja; Lars Skjærven; Oscar Aubi; Jarl Underhaug; David J López; Igor Arregi; Marián Alonso-Mariño; Andoni Cuevas; José A Rodríguez; Aurora Martinez; Sonia Bañuelos
Journal:  Sci Rep       Date:  2017-10-24       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.